Brandi French, MD
Vascular Neurology · Columbia, MONPI 1659368413
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,054 of the $3,181 with a category attached, or 64.6%. Medtronic accounts for 70.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,806, 5.6 times the $322 reported in 2019.
Across 44 payments — averaging $72.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Penumbra, Inc.$303
- Siemens Medical Solutions USA, Inc.$136
- Stryker$118
- Imperative Care, Inc$90
- Amneal Pharmaceuticals LLC$71
- plus $233 from 7 others
What the payments were for
- Travel & lodging$1,12835%
- Food & beverage$2,05465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $2,230 |
| Penumbra, Inc. | 5 | $303 |
| Siemens Medical Solutions USA, Inc. | 1 | $136 |
| Stryker | 1 | $118 |
| Imperative Care, Inc | 1 | $90 |
| Amneal Pharmaceuticals LLC | 1 | $71 |
| Abbott | 1 | $51 |
| Inspire Medical Systems, Inc. | 1 | $49 |
| Bayer | 1 | $40 |
| Boston Scientific | 1 | $39 |
| AbbVie | 1 | $28 |
| Genentech USA, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pipeline$182
- LINQ II$172
- Penumbra Jet 7$136
- Penumbra System$136
- TREVO$118
How this compares
Too few vascular neurology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 48 | $1,132 |
| Carbamazepine | 14 | $1,057 |
| Nortriptyline Hcl | 16 | $516 |
| Gabapentin | 11 | $389 |
| Lamotrigine | 11 | $241 |
| Topiramate | 25 | $185 |
| Morphine Sulfate | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Columbia
- Adnan QureshiColumbia$60K
- Camilo GomezColumbia$6K
- Alibay JafarliColumbia$168
- Guillermo LinaresSaint Louis$11K
- Chizoba EzepueBridgeton$8K
- Weston GordonSaint Louis$5K
- Chike IlorahSaint Louis$5K
- Amer AlshekhleeBridgeton$4K
- Abdallah AmirehSaint Joseph$3K
- Randall EdgellSaint Louis$687
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.